This product is a IL-4 expressing oncolytic herpes simplex virus, which is based on HSV-1 with ICP27 deleted. ICP27 is highly cytotoxic probably due to its secondary role of preventing the splicing of pre-mRNAs in favour of translation from the mainly unspliced hepes RNAs. Deletion of ICP27 might produce a safer and less cytotoxic system when combined with other oncolytic-rendered modifications. This product can be used in oncolytic virotherapy research and further recombinant HSV construction.
Specifications
Family
Herpesviridae
Species
Herpes simplex virus
Serotype
Herpes simplex virus 1
Backbone
HSV-1 (ΔICP27)
Backbone Background
Herpes simplex virus 1 and 2 (HSV-1 and HSV-2), also known as human herpesvirus 1 and 2 (HHV-1 and HHV-2), are two members of the human Herpesviridae family, a set of viruses that produce viral infections in the majority of humans. Modified Herpes simplex virus is considered as a potential therapy for cancer and has been extensively clinically tested to assess its oncolytic ability.
The interleukin 4 (IL4, IL-4) is a cytokine that induces differentiation of naive helper T cells (Th0 cells) to Th2 cells. Upon activation by IL-4, Th2 cells subsequently produce additional IL-4 in a positive feedback loop. The cell that initially produces IL-4, thus inducing Th2 differentiation, has not been identified, but recent studies suggest that basophils may be the effector cell. It is closely related and has functions similar to Interleukin 13.
Customer Reviews and Q&As
There are currently no customer reviews or questions for IL-4-expressing Oncolytic Herpes Simplex Virus 1 (ΔICP27), hTERT-IL-4 (CyOV-0084XY). Click the button below to contact us or submit your feedback about this product.
All products and services are for Research Use Only. Not For Clinical Use.